Physician profile
Anna Clark
NPI 1457705733
$17,128.75
in general payments reported to CMS, 2019-2025
38 companies · $4,087 in 2025
The $4,087 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $439 · 2021: $2,108 · 2022: $2,511 · 2023: $4,151 · 2024: $3,523 · 2025: $4,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,531.87 |
| Education | $228.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,444.54 | 2020-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $1,156.60 | 2020-2025 | |
| Galderma Laboratories, L.P. | $994.48 | 2019-2025 | Epsolay, Aklief, Nemluvio |
| Regeneron Healthcare Solutions, INC. | $961.08 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $947.18 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $881.97 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $864.88 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $794.44 | 2020-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $786.62 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $708.37 | 2020-2025 | Tremfya |
| Dermavant Sciences, INC. | $705.50 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $558.75 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $547.65 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $538.83 | 2021-2025 | Winlevi |
| E.R. Squibb & Sons, L.L.C. | $476.08 | 2022-2025 | Sotyktu |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $406.78 | 2022-2025 | Klisyri, Seysara |
| Mayne Pharma Commercial LLC | $391.91 | 2020-2025 | |
| Genzyme Corporation | $322.20 | 2020-2025 | |
| Kerecis Limited | $285.44 | 2022-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Botanix Sb INC | $234.09 | 2025 | Sofdra |
| Genentech USA, INC. | $150.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.25 | 2023-2024 | Spevigo |
| Janssen Scientific Affairs, LLC | $124.24 | 2025 | Tremfya |
| Journey Medical Corporation | $113.99 | 2022-2025 | |
| Biofrontera INC. | $81.34 | 2020-2025 | |
| Allergan, INC. | $75.89 | 2022 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $66.10 | 2025 | Acthar |
| Organon LLC | $56.31 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $52.34 | 2021 | |
| Ani Pharmaceuticals, INC. | $48.53 | 2024 | Purified Cortrophin Gel |
| Dermira, INC. | $33.25 | 2020-2021 | |
| Epi Health, LLC | $29.25 | 2021-2022 | |
| Sandoz INC. | $23.72 | 2020 | |
| Kyowa Kirin, INC. | $17.20 | 2023 | Poteligeo |
| Acelrx Pharmaceuticals, INC. | $13.79 | 2021 | |
| Fresenius Kabi USA, LLC | $13.63 | 2023 | Idacio |
| Fidia Pharma USA INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.